HK:2565 Stock Latest News
Company AnnouncementsPegBio Plans Discounted Placement of 26.813 Million H Shares1h ago2565
Company AnnouncementsPegBio Calls 2026 EGM to Replace Auditor and Redirect IPO Proceeds1w ago2565
Company AnnouncementsPegBio Seeks Cost-Efficient Switch From KPMG to RCHK as 2026 Auditor1M ago2565
Company AnnouncementsPegBio Redirects IPO Funds to Speed PB-119 Commercialization1M ago2565
Company AnnouncementsPegBio Partners SN BioScience to Advance Long-Acting Metabolic Peptide Candidates2M ago2565
Company AnnouncementsPegBio Deepens Losses as Paidakang Commercialization and Metabolic Pipeline Gain Traction2M ago2565Company AnnouncementsPegBio’s Diabetes Drug Paidakang Enters Nationwide Clinical Use, Triggers Second Royalty Milestone3M ago2565
Company AnnouncementsPegBio Teams with Rani Therapeutics to Pursue Oral Metabolic Therapies3M ago2565
Company AnnouncementsPegBio Diabetes Drug Clears Key Hurdle Toward China Reimbursement Listing4M ago2565
Company AnnouncementsPegBio Completes H-Share Full Circulation, Boosting Free Float in Hong Kong4M ago2565
Company AnnouncementsPegBio Clarifies Board Composition and Governance Committee Roles4M ago2565
Company AnnouncementsPegBio Wins Strong Shareholder Backing for Capital Moves and Governance Changes at AGM4M ago2565Company AnnouncementsPegBio Secures First HK$61 Million Royalty as Paidakang Diabetes Drug Enters Active Commercial Rollout5M ago2565
Company AnnouncementsPegBio Sets 2025 AGM to Seek Capital Increase and Broad Share Issuance Mandate5M ago2565
Company AnnouncementsPegBio’s CR059 Wins EASD 2026 Oral Slot, Boosting Circular RNA Metabolic Pipeline5M ago2565- Company AnnouncementsPegBio’s Diabetes Drug Visepegenatide Reaches Key Milestone in China’s Insurance Access Process5M ago2565
Company AnnouncementsPegBio reshapes board as independent director resigns and new candidate proposed5M ago2565
Company AnnouncementsPegBio outlines board composition and governance committee roles5M ago2565
Company AnnouncementsPegBio Cornerstone Investor Extends Lock-Up on 3.37% H-Share Stake6M ago2565Company AnnouncementsPegBio Advances H Share Full Circulation Plan After CSRC Filing Approval6M ago2565
Company AnnouncementsPegBio’s Long-Acting Diabetes Candidate CR059 Gains Late-Breaking Spotlight at ADA 20267M ago2565